Impact BioMedical, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Impact BioMedical, INC. (IBO) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $287.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2025-11-07
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $287.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $574.00K.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $861.00K.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $279.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2025-09-30 | $287.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $574.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $861.00K 10-Q · filed 2025-05-14 |
| 2024-09-30 | $279.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $557.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $835.00K 10-Q · filed 2024-05-10 |
| 2023-09-30 | $279.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $557.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |